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TransplantatABSTRACT
T-cell large granular lymphocytic (T-LGL) leukemia is a rare clonal proliferation pre-
senting with cytopenia, splenomegaly, and autoimmune manifestations. It has rarely been
described in recipients of solid organ transplants.
We report the clinical case of a young kidney transplant recipient that developed T-LGL
leukemia 3 years after kidney transplantation. The disorder manifested with a severe form
of autoimmune hemolytic anemia in the absence of other laboratory abnormalities.
The anemia was successfully treated with an intense course of corticosteroids ands
witch of immunosuppressive therapy from a calcineurin inhibitor to sirolimus, a mamma-
lian target of rapamycin inhibitor.
Our case shows that autoimmune hemolytic anemia can be a life-threatening manifestation
of T-LGL disease. The antiproliferative effects of sirolimus may be useful in the treatment
of symptoms of T-LGL leukemia in kidney transplantation.*Address correspondence to Gaetano Alfano, Nephrology
Dialysis and Transplant Unit, University Hospital of Modena, Via
del Pozzo, 71, 41124 Modena, Italy. E-mail: gaetano.alfano@
unimore.itT-CELL large granular lymphocytic (T-LGL) leukemia isa clonal proliferation of large granular lymphocytes.
Cytopenia, splenomegaly, and autoimmune phenomena are
the main manifestations of this lymphoproliferative disease
[1e3]. T-LGL leukemia has beenrarely described in re-
cipients of solid organ transplants [4,5]. Prognosis of the
disease is generally favorable since progression to the ma-
lignant variant is rarely reported in the general population
[6]. Treatment is based on immunosuppressive therapy
including cyclosporin, cyclophosphamide, and metho-
trexate, but there is a lack of specific guidelines [7]. We
report a case of T-LGL leukemia in a young recipient of a
kidney transplant (KT) manifesting with hemolytic autoim-
mune anemia. Treatment with corticosteroids and a thera-
peutic switch from tacrolimus to sirolimus resolved the
severe episode of anemia and ensured good graft function.
CASE PRESENTATION
A 21-year-old Caucasian man with a second kidney transplant
presented at our office for progressive weakness and dizziness. He
had a diagnosis of end-stage renal disease due to congenital renal
dysplasia at the age of 8 years. After 1 year of peritoneal dialysis, he
received cadaveric kidney transplantation that failed as a result of
chronic humoral rejection after 9 years.vier Inc. All rights reserved.
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ion Proceedings, 52, 1617e1618 (2020)At the age of 19 years, after 1 year of hemodialysis, a second
kidney transplant from a cadaveric donor was performed. Induction
immunosuppressive therapy consisted of antithymocyte globulin
and high doses of corticosteroids. A maintenance immunosup-
pressive regimen was based on tacrolimus, corticosteroids, and
mycophenolic acid. The post-transplantation course was uneventful,
and the patient was discharged with normal renal function. A
diagnosis of asymptomatic T-LGL leukemia was performed after
the detection of relative lymphocytosis noted on the complete blood
count. Bone marrow biopsy confirmed the presence of clonal LGLs
of T-cell lineage in the marrow. Diagnostic work-up showed mild
splenomegaly (longitudinal diameter of 13 cm) and the absence of
autoimmune phenomena.
Three years after transplantation, the patient was admitted to
hospital with severe anemia (7 g/dL) without other complete blood
count abnormalities. Hewas apyretic and with normal blood pressure
on clinical examination. In absence of evident bleeding, he denied
melena, hematemesis, or epistaxis. A diagnosis of autoimmune he-
molytic anemia associated with T-LGL leukemia was made after the0041-1345/20
https://doi.org/10.1016/j.transproceed.2020.02.183
1617
1618 ALFANO, FERRARI, FONTANA ET ALdetection of warm antibodies (IgA and IgG) on Coombs test. High
direct bilirubin, high lactate dehydrogenase, and low haptoglobin
concentration supported the diagnosis of intravascular destruction
of red blood cells.
The anemia was treated with blood transfusions and corticoste-
roids at a dosage of 100 mg daily for 10 days, then tapered to 1 mg/
kg for 5 weeks. In order to control the lymphoproliferative disorder,
immunosuppressive therapy was switched from tacrolimus to siro-
limus, a mammalian target of rapamycin inhibitor with well-known
antiproliferative properties.
Forty-two months after successful treatment of hemolytic auto-
immune anemia, serum hemoglobin level was stable to 13 g/dL and
renal function was normal (serum creatinine 1 mg/dL). The rise of
the mean fluorescence intensity of a pre-existing donor-specific
antibody prompted the prudential conversion from sirolimus to
tacrolimus after 35 months from the therapeutic switch. Despite
sirolimus withdrawal, T-LGL leukemia did not progress to a
malignant variant and LGL count was stable at 1000 cells/mm3.
DISCUSSION
We presented to the best of our knowledge the first case of
hemolytic autoimmune anemia resulting from T-LGL leu-
kemia in a recipient of KT. T-LGL leukemia is a rare and
indolent lymphoproliferative disease which occurs with
cytopenia and autoimmune phenomena.Anemia is present in
about half of patients, and 20% of them require blood
transfusions. T-LGL leukemia is considered to be an indolent
disorder by the hematologic community and is treated with
immunosuppressive therapy. In our case, we described the
late and severe manifestations of T-LGL leukemia in a young
recipient of KT. Although anemia was easily treated with
corticosteroids, this hematologic disease threatened patient
life and graft survival. Namely, the transfusions of multiple
packed red blood cell units exposed the patient to different
antigens that could have increased the risk of allograft
rejection. The use of additional immunosuppressive agents
further reduced the immune competence of an already
immunocompromised patient. In addition, administration ofhigh-dose corticosteroids may have increased the risk of
metabolic and vascular complications in our patient. The
use of sirolimus is an attractive option for patients with a
post-transplant lymphoproliferative disorder (PTLD) [8].
However, theminor immunosuppressive potency of sirolimus
compared to a calcineurin inhibitor should be balanced
against its well-known antiproliferative activity [9]. In light of
these findings, we suggest a careful follow-up in all patients
with T-LGL leukemia for the risk of late and sudden devel-
opment of severe manifestations. Furthermore, if the patient
is treated with sirolimus, it is advisable to regularly check
renal function, urine examination, and de novo donor-
specific antibody formation.REFERENCES
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